Logo image of LABP

LANDOS BIOPHARMA INC (LABP) Stock Fundamental Analysis

USA - NASDAQ:LABP - US5150692011 - Common Stock

22.93 USD
+0.13 (+0.58%)
Last: 5/23/2024, 8:16:35 PM
22.91 USD
-0.02 (-0.09%)
After Hours: 5/23/2024, 8:16:35 PM
Fundamental Rating

2

Overall LABP gets a fundamental rating of 2 out of 10. We evaluated LABP against 192 industry peers in the Pharmaceuticals industry. LABP has a great financial health rating, but its profitability evaluates not so good. LABP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LABP has reported negative net income.
In the past year LABP has reported a negative cash flow from operations.
LABP had negative earnings in each of the past 5 years.
In the past 5 years LABP always reported negative operating cash flow.
LABP Yearly Net Income VS EBIT VS OCF VS FCFLABP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of LABP (-82.94%) is worse than 72.16% of its industry peers.
Looking at the Return On Equity, with a value of -107.09%, LABP is doing worse than 60.82% of the companies in the same industry.
Industry RankSector Rank
ROA -82.94%
ROE -107.09%
ROIC N/A
ROA(3y)-61.94%
ROA(5y)-62.38%
ROE(3y)-73.25%
ROE(5y)-81.32%
ROIC(3y)N/A
ROIC(5y)N/A
LABP Yearly ROA, ROE, ROICLABP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LABP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LABP Yearly Profit, Operating, Gross MarginsLABP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for LABP has been reduced compared to 1 year ago.
The number of shares outstanding for LABP has been reduced compared to 5 years ago.
LABP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LABP Yearly Shares OutstandingLABP Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
LABP Yearly Total Debt VS Total AssetsLABP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

LABP has an Altman-Z score of -3.20. This is a bad value and indicates that LABP is not financially healthy and even has some risk of bankruptcy.
LABP has a Altman-Z score (-3.20) which is comparable to the rest of the industry.
LABP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.2
ROIC/WACCN/A
WACCN/A
LABP Yearly LT Debt VS Equity VS FCFLABP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 4.43 indicates that LABP has no problem at all paying its short term obligations.
The Current ratio of LABP (4.43) is comparable to the rest of the industry.
A Quick Ratio of 4.43 indicates that LABP has no problem at all paying its short term obligations.
With a Quick ratio value of 4.43, LABP perfoms like the industry average, outperforming 59.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.43
Quick Ratio 4.43
LABP Yearly Current Assets VS Current LiabilitesLABP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 43.00% over the past year.
EPS 1Y (TTM)43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

LABP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.15% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y35.44%
EPS Next 2Y22.61%
EPS Next 3Y18.15%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LABP Yearly Revenue VS EstimatesLABP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 5M 10M 15M
LABP Yearly EPS VS EstimatesLABP Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LABP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LABP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LABP Price Earnings VS Forward Price EarningsLABP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LABP Per share dataLABP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

LABP's earnings are expected to grow with 18.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.61%
EPS Next 3Y18.15%

More info and screens

0

5. Dividend

5.1 Amount

LABP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LANDOS BIOPHARMA INC

NASDAQ:LABP (5/23/2024, 8:16:35 PM)

After market: 22.91 -0.02 (-0.09%)

22.93

+0.13 (+0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-09 2024-05-09/bmo
Earnings (Next)08-07 2024-08-07/bmo
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners6.69%
Ins Owner ChangeN/A
Market Cap71.77M
Revenue(TTM)N/A
Net Income(TTM)-24.80M
Analysts47.5
Price Target12.96 (-43.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-23.14%
Min EPS beat(2)-40.2%
Max EPS beat(2)-6.08%
EPS beat(4)1
Avg EPS beat(4)-1.64%
Min EPS beat(4)-40.2%
Max EPS beat(4)43.85%
EPS beat(8)5
Avg EPS beat(8)11.13%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)154.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.37%
EPS NY rev (1m)0%
EPS NY rev (3m)16.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.1
P/tB 3.1
EV/EBITDA N/A
EPS(TTM)-3.99
EYN/A
EPS(NY)-1.72
Fwd EYN/A
FCF(TTM)-6.65
FCFYN/A
OCF(TTM)-6.65
OCFYN/A
SpS0
BVpS7.4
TBVpS7.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -82.94%
ROE -107.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.94%
ROA(5y)-62.38%
ROE(3y)-73.25%
ROE(5y)-81.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.43
Quick Ratio 4.43
Altman-Z -3.2
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.89%
EPS Next Y35.44%
EPS Next 2Y22.61%
EPS Next 3Y18.15%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-48.98%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y33.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.89%
OCF growth 3YN/A
OCF growth 5YN/A

LANDOS BIOPHARMA INC / LABP FAQ

Can you provide the ChartMill fundamental rating for LANDOS BIOPHARMA INC?

ChartMill assigns a fundamental rating of 2 / 10 to LABP.


What is the valuation status of LANDOS BIOPHARMA INC (LABP) stock?

ChartMill assigns a valuation rating of 0 / 10 to LANDOS BIOPHARMA INC (LABP). This can be considered as Overvalued.


What is the profitability of LABP stock?

LANDOS BIOPHARMA INC (LABP) has a profitability rating of 0 / 10.


Can you provide the financial health for LABP stock?

The financial health rating of LANDOS BIOPHARMA INC (LABP) is 7 / 10.